DE60128445D1 - Mutiertes cyclin g1 protein - Google Patents

Mutiertes cyclin g1 protein

Info

Publication number
DE60128445D1
DE60128445D1 DE60128445T DE60128445T DE60128445D1 DE 60128445 D1 DE60128445 D1 DE 60128445D1 DE 60128445 T DE60128445 T DE 60128445T DE 60128445 T DE60128445 T DE 60128445T DE 60128445 D1 DE60128445 D1 DE 60128445D1
Authority
DE
Germany
Prior art keywords
protein
mutated cyclin
animal
cyclin
mutated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60128445T
Other languages
English (en)
Other versions
DE60128445T2 (de
Inventor
Erlinda Maria Gordon
Frederick L Hall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California USC filed Critical University of Southern California USC
Application granted granted Critical
Publication of DE60128445D1 publication Critical patent/DE60128445D1/de
Publication of DE60128445T2 publication Critical patent/DE60128445T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Vascular Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE60128445T 2000-03-02 2001-03-01 Mutiertes cyclin g1 protein Expired - Lifetime DE60128445T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US517832 1983-07-27
US51783200A 2000-03-02 2000-03-02
PCT/IB2001/000303 WO2001064870A2 (en) 2000-03-02 2001-03-01 Mutated cyclin g1 protein

Publications (2)

Publication Number Publication Date
DE60128445D1 true DE60128445D1 (de) 2007-06-28
DE60128445T2 DE60128445T2 (de) 2008-01-10

Family

ID=24061405

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60128445T Expired - Lifetime DE60128445T2 (de) 2000-03-02 2001-03-01 Mutiertes cyclin g1 protein

Country Status (10)

Country Link
EP (1) EP1259605B1 (de)
JP (2) JP2003525607A (de)
AT (1) ATE362535T1 (de)
AU (3) AU2001234025B2 (de)
CA (1) CA2401545C (de)
DE (1) DE60128445T2 (de)
ES (1) ES2287098T3 (de)
IL (2) IL151527A0 (de)
NZ (1) NZ521070A (de)
WO (1) WO2001064870A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002044394A2 (en) 2000-11-29 2002-06-06 University Of Southern California Targetet retoviral vectors for cancer immunotherapy
DE10157454B4 (de) * 2001-11-23 2005-07-07 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren und Vorrichtung zum Erzeugen einer Kennung für ein Audiosignal, Verfahren und Vorrichtung zum Aufbauen einer Instrumentendatenbank und Verfahren und Vorrichtung zum Bestimmen der Art eines Instruments
JP2006524057A (ja) * 2003-04-21 2006-10-26 エペイウス バイオテクノロジーズ， インコーポレイテッド 疾患を処置するための方法および組成物
US20070178066A1 (en) 2003-04-21 2007-08-02 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
WO2013177187A2 (en) 2012-05-22 2013-11-28 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
JP5892666B2 (ja) * 2014-03-14 2016-03-23 国立大学法人大阪大学 細胞死促進剤
US20210038684A1 (en) 2019-06-11 2021-02-11 Alkermes Pharma Ireland Limited Compositions and Methods for Cancer Immunotherapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU724439B2 (en) * 1995-11-01 2000-09-21 University Of Southern California Expression of cyclin G1 in tumours

Also Published As

Publication number Publication date
ATE362535T1 (de) 2007-06-15
EP1259605A2 (de) 2002-11-27
WO2001064870A2 (en) 2001-09-07
AU2008221564A1 (en) 2008-10-16
CA2401545C (en) 2011-01-04
CA2401545A1 (en) 2001-09-07
AU2001234025B2 (en) 2005-07-07
DE60128445T2 (de) 2008-01-10
IL151527A0 (en) 2003-04-10
JP2011160815A (ja) 2011-08-25
EP1259605B1 (de) 2007-05-16
ES2287098T3 (es) 2007-12-16
NZ521070A (en) 2004-07-30
WO2001064870A3 (en) 2002-01-31
IL151527A (en) 2010-12-30
AU3402501A (en) 2001-09-12
JP2003525607A (ja) 2003-09-02

Similar Documents

Publication Publication Date Title
DK1641483T3 (da) Fusionsproteiner
HK1103363A1 (en) Treatment of glycogen storage diseases type ii ii
CY1111371T1 (el) Αντισωματα bag3 για χρηση σε ερευνα, διαγνωση και θεραπεια ασθενειων που σχετιζονται με κυτταρικο θανατο
BR0209645A (pt) Oxazolo- e furopirimidinas e seu uso como medicamentos
ATE374251T1 (de) Zusammensetzungen zur gentherapie von diabetes
DE60019894D1 (de) Phenantrhridin-n-oxides mit pde-iv hemmender wirkung
ATE362535T1 (de) Mutiertes cyclin g1 protein
MXPA04001256A (es) Productos de combinacion de derivados de propanolamina aril substituidos con otros ingredientes activos y su uso.
DE60025327D1 (de) 6-arylphenanthridine mit pde-iv hemmender wirkung
EA200500934A1 (ru) Соединения, модулирующие активность киназного белка множественных линий, и способы лечения нейродегенеративных и воспалительных заболеваний
DK1169340T3 (da) Lantibiotikum
BR0009170A (pt) ácidos nucléicos akt, polipeptìdeos e uso dos mesmos
ATE295352T1 (de) Phenanthridine-n-oxide mit pde-iv hemmender wirkung
BR0115534A (pt) Luciferases isoladas assim como seu emprego
HK1074840A1 (en) Novel dithiolopyrrolones with therapeutic activity
ATE459643T1 (de) Ee3-proteinfamilie und zugrundeliegende dna- sequenzen
AU2001249267A1 (en) Methods and compositions for elucidating protein expression profiles in cells
CY1118235T1 (el) Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ii
FR2813606B1 (fr) Proteine bard1 tronquee, et ses applications diagnostiques et therapeutiques
AU6301398A (en) Arrestable therapeutic viral agent
NO20005321L (no) Vertskodet protein uttrykt i Mareks sykdoms (MDV) infiserte celler og antistoffer til dette
ATE405583T1 (de) Human kinase interacting protein 2 (kip2)-related gene variant (kip2v1) im zusammenhang mit prostatakrebs

Legal Events

Date Code Title Description
8364 No opposition during term of opposition